Pfizer-Led $62M Bet Signals a New Era for Autoimmune Disease Treatment

NEW YORK, NY – June 25, 2026 – A significant vote of confidence from some of biotechnology’s most influential investors is fueling what could be the next major leap in treating severe autoimmune diseases. Oblenio Bio, a company built to advance a single promising asset, announced today it has closed an oversubscribed $62 million Series B financing round. The investment, led by Pfizer’s venture arm Pfizer Ventures, with participation from GV (formerly Google Ventures), Deep Track Capital, and founding investor Aditum Bio, is a powerful endorsement of a novel therapeutic designed to fundamentally reset the body’s malfunctioning immune system.

The funds are earmarked to push LBL-051, a first-of-its-kind tri-specific T-cell engager, into human clinical trials. Discovered and engineered in the labs of Chinese biotech firm Leads Biolabs, LBL-051 represents a new front in a battle that millions of patients fight daily against conditions like lupus and multiple sclerosis. The financing not only validates the cutting-edge science behind the drug but also highlights a powerful model of global collaboration poised to bring innovation from a proprietary platform in Nanjing to patients worldwide.

A Tri-Specific Approach to Immune Reset

For decades, the standard of care for autoimmune diseases has involved broadly suppressing the immune system, a blunt approach that can leave patients vulnerable to infection and other side effects. More recently, targeted therapies have offered greater precision, but achieving lasting, drug-free remission remains the holy grail. LBL-051 aims to achieve just that through a sophisticated mechanism known as a tri-specific T-cell engager.

The therapy works by acting as a molecular matchmaker. It has three arms: two that grab onto markers found on rogue B-cells and plasma cells (CD19 and BCMA), and a third that grabs onto a patient’s own T-cells (via CD3), the natural-born killers of the immune system. By bringing these cells together, LBL-051 directs a patient’s T-cells to selectively eliminate the B-cell and plasma cell populations that drive autoimmune disease.

This dual-targeting of CD19 and BCMA is what sets LBL-051 apart. While CAR-T therapies have shown remarkable success in cancer and are being explored in autoimmunity, they require a complex and costly process of engineering a patient's cells outside the body. Furthermore, a new wave of bispecific T-cell engagers, which target just one B-cell marker alongside T-cells, is attracting intense industry interest, evidenced by recent multi-billion-dollar acquisitions by UCB and Gilead Sciences. Oblenio’s tri-specific approach, however, is designed to provide a more comprehensive sweep, depleting a broader spectrum of problematic cells to induce a deeper and more durable immune reset.

Crucially, preclinical data presented at the 2026 European Congress of Rheumatology (EULAR 2026) suggests LBL-051 can do this with a remarkable degree of safety. In non-human primate studies, the therapy led to the complete depletion of targeted immune cells in both blood and tissue. Upon recovery, the subjects’ bodies began producing new, immature B-cells—a biological signature consistent with the immune “reboot” seen in patients who achieve long-term remission. Perhaps most importantly, the treatment did not trigger cytokine release syndrome (CRS), a potentially life-threatening inflammatory response that has been a persistent concern with other T-cell-engaging therapies.

The Power of the Platform and Partnership

LBL-051’s journey from a lab in Nanjing to a venture-backed U.S. biotech is a case study in modern drug development. The molecule was born from the proprietary LeadsBody platform developed by Leads Biolabs, a clinical-stage company founded in 2012. The platform is designed to engineer complex multi-specific antibodies with precision, fine-tuning their binding affinities to maximize efficacy while minimizing toxicity.

This innovation caught the eye of Aditum Bio, a U.S. venture capital firm with a unique “company creation” model. Co-founded by former Novartis leaders Joe Jimenez and Mark Fishman, Aditum scouts for promising preclinical assets and builds focused, standalone companies around them. In 2024, Aditum formed Oblenio Bio through an exclusive licensing agreement with Leads Biolabs, providing the strategic and financial framework to accelerate LBL-051’s path to the clinic.

“The strong investor interest in Oblenio’s Series B financing validates the potential of our LeadsBody platform to generate differentiated assets,” said Dr. Xiaoqiang Kang, Founder, Chairman and CEO of Leads Biolabs. “We are pleased to see this financing significantly accelerate LBL-051’s path to the clinic.”

As the originating innovator, Leads Biolabs remains a key partner, eligible for up to $579 million in milestone payments and future royalties. The collaboration is further cemented by Dr. Kang’s appointment as a Board Observer at Oblenio, ensuring a continued flow of expertise between the platform creators and the drug developers. This cross-border model leverages Chinese scientific innovation and U.S. clinical development and venture capital expertise, creating a streamlined pathway for a globally relevant therapy.

Big Pharma's Bet on a New Autoimmune Frontier

The composition of the investor syndicate speaks volumes about the perceived potential of LBL-051. A lead investment from Pfizer Ventures is more than just capital; it is a strategic signal from one of the world’s largest pharmaceutical companies. Pfizer’s deep expertise in inflammation and immunology suggests a belief that Oblenio’s approach could represent a paradigm shift. According to one industry analyst, corporate venture arms like Pfizer’s invest to gain a window into disruptive technologies that could one day become part of their own pipeline.

The participation of GV and Deep Track Capital further solidifies this confidence. GV is known for its long-term bets on transformative technologies across sectors, while Deep Track Capital brings deep, specialized life sciences expertise. For these investors, LBL-051 is not just an incremental improvement but a potential platform for durable cures in a field of immense unmet need.

As Oblenio Bio prepares to initiate its first-in-human trials later this year, the $62 million infusion provides the necessary runway to translate its robust preclinical data into clinical reality. The journey ahead will be challenging, but the convergence of sophisticated science, a novel partnership model, and strategic capital has set the stage for a therapy that could one day offer lasting hope to patients who currently have none.